{
    "name": "pembrolizumab",
    "comment": "Rx",
    "other_names": [
        "Keytruda"
    ],
    "classes": [
        "Antineoplastics",
        "Monoclonal Antibody",
        "PD-1/PD-L1 Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/keytruda-pembrolizumab-999962",
    "pregnancy": {
        "common": [
            "Based on its mechanism of action, fetal harm may occur when administered to a pregnant woman",
            "No human data available informing the risk of embryo-fetal toxicity"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal models, the PD-1/PD-L1 signaling pathway is important in the maintenance of pregnancy through induction of maternal immune tolerance to fetal tissue",
                    "Human IgG4 (immunoglobulins) are known to cross the placenta; therefore, pembrolizumab can potentially be transmitted from the mother to the developing fetus"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise females of reproductive potential to use effective contraception during treatment and for at least 4 months following final dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Maternal IgG is known to be present in human milk; effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to this drug are unknown",
            "No studies conducted to assess impact of pembrolizumab on milk production or its presence in breast milk",
            "Instruct women to discontinue nursing during treatment and for 4 months after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Monitor for signs and symptoms of adrenal insufficiency; administer corticosteroids and hormone replacement as clinically indicated; withhold therapy for moderate (Grade 2) adrenal insufficiency and withhold or discontinue for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency",
                "Solid organ transplant rejection reported in postmarketing setting; treatment increases risk of rejection in solid organ transplant recipients; consider benefit of treatment versus risk of possible organ rejection",
                "Infusion-related reactions, including severe and life-threatening reactions, reported; monitor for signs and symptoms of infusion-related reactions including rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever; interrupt or slow rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions; for severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions, stop infusion and permanently discontinue therapy",
                "Hypophysitis reported; monitor for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency)",
                "Thyroid disorders can occur; monitor for changes in thyroid function (at the start of treatment, periodically during treatment, and as clinically indicated) and for clinical signs and symptoms of thyroid disorders",
                "Based on its mechanism of action, fetal harm may occur when administered to a pregnant woman (see Pregnancy)",
                "In two randomized clinical trials in patients with multiple myeloma, the addition of pembrolizumab to a thalidomide analogue plus dexamethasone resulted in increased mortality; treatment of patients with multiple myeloma with a PD-1 or PDL1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials"
            ],
            "specific": [
                {
                    "type": "Immune-mediated adverse effects",
                    "description": [
                        "Also see Dosage Modifications",
                        "Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously;",
                        "Immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody",
                        "While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies",
                        "For patients with TNBC treated in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated",
                        "Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies",
                        "Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions",
                        "Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment",
                        "In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection; institute medical management promptly, including specialty consultation as appropriate",
                        "Clinical trials reported immune-mediated pneumonitis, colitis, hepatitis, nephritis and other immune-mediated adverse reactions (eg, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures arising in a patient with inflammatory foci in brain parenchyma, myasthenic syndrome, optic neuritis, and rhabdomyolysis)",
                        "Immune-mediated rashes, including SJS, TEN, exfoliative dermatitis, and bullous pemphigoid, reported; monitor for suspected severe skin reactions and exclude other causes",
                        "Immune-mediated endocrinopathies (eg, adrenal insufficiency, changes in thyroid function, type 1 diabetes mellitus including diabetic ketoacidosis) reported",
                        "Immune-mediated complications, including fatal events, occurred in patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) after being treated with pembrolizumab",
                        "Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning, and steroid- requiring febrile syndrome (without an identified infectious cause); these complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT",
                        "Follow patients closely for evidence of transplant-related complications and intervene promptly; consider benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT",
                        "Institute medical management promptly, including specialty consultation as appropriate"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "65"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "65"
        },
        {
            "name": "Hypertension",
            "percent": "65"
        },
        {
            "name": "Diarrhea",
            "percent": "64"
        },
        {
            "name": "Decreased appetite",
            "percent": "52"
        },
        {
            "name": "Hypothyroidism",
            "percent": "51"
        },
        {
            "name": "Nausea",
            "percent": "48"
        },
        {
            "name": "Stomatitis",
            "percent": "43"
        },
        {
            "name": "Vomiting",
            "percent": "39"
        },
        {
            "name": "Decreased weight",
            "percent": "36"
        },
        {
            "name": "Abdominal pain",
            "percent": "33"
        },
        {
            "name": "Headache",
            "percent": "33"
        },
        {
            "name": "Constipation",
            "percent": "32"
        },
        {
            "name": "Urinary tract infection",
            "percent": "31"
        },
        {
            "name": "Dysphoria",
            "percent": "29"
        },
        {
            "name": "Hemorrhagic events",
            "percent": "28"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "27"
        },
        {
            "name": "Palmar",
            "percent": "26"
        },
        {
            "name": "plantar erythrodysesthesia syndrome",
            "percent": "24"
        },
        {
            "name": "Dyspnea",
            "percent": "21"
        },
        {
            "name": "Cough",
            "percent": "21"
        },
        {
            "name": "Rash",
            "percent": "9"
        },
        {
            "name": "Hypertension",
            "percent": "6"
        },
        {
            "name": "Abdominal pain",
            "percent": "5"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "4"
        },
        {
            "name": "Hemorrhage",
            "percent": "4"
        },
        {
            "name": "Fatigue",
            "percent": "4"
        },
        {
            "name": "Nausea",
            "percent": "4"
        },
        {
            "name": "Confusional state",
            "percent": "4"
        },
        {
            "name": "Pleural effusion",
            "percent": "3"
        },
        {
            "name": "Adrenal insufficiency",
            "percent": "3"
        },
        {
            "name": "Colitis",
            "percent": "3"
        },
        {
            "name": "Dyspnea",
            "percent": "3"
        },
        {
            "name": "Pyrexia",
            "percent": "3"
        },
        {
            "name": "Vomiting",
            "percent": "4"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "or",
            "percent": "4"
        },
        {
            "name": "Potassium increased",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "or",
            "percent": "3"
        },
        {
            "name": "Rash",
            "percent": "4"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "or",
            "percent": "4"
        },
        {
            "name": "Cough",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "or",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Grade",
            "percent": null
        },
        {
            "name": "or",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Grade",
            "percent": null
        },
        {
            "name": "or",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Neck pain",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        }
    ]
}